Myeloma Patients Move to Australia for Cancer Treatment
Here’s a breakdown of the key information from the provided text:
Main Issue: New Zealand cancer patients, specifically those wiht myeloma, are traveling to Australia (and possibly elsewhere) to access the drug daratumumab, which is not fully funded or readily available in New zealand.
Key Points:
* Daratumumab’s Effectiveness: Daratumumab has shown meaningful improvements in survival rates for myeloma patients in clinical trials – potentially adding four years or more of life.
* Political Promises: Christopher Luxon (National party leader) previously stated a desire to improve cancer treatment access in New Zealand, allowing people to fight cancer at home.
* Doctor’s Frustration: Consultant haematologist Dr. Rodger Tiedemann is critical of the Cancer Control Agency’s decision not to prioritize daratumumab. He believes their analysis of trial data was flawed and deliberately downplayed the drug’s benefits. He states they ignored the vast majority of trial data.
* Patient Impact: The lack of access to daratumumab means patients are missing out on potentially valuable years with their families.The article references another story about a family moving to Australia for a different drug (Trikafta for cystic fibrosis) to illustrate the desperation patients face.
* Limited funding: Tiedemann notes that additional funding for this drug would only benefit a small percentage of blood cancer patients (under 1%).
* Agency Concerns: The Cancer Control Agency has acknowledged delays in treatment access are stressful for patients (link provided).
In essence, the article highlights a gap in New Zealand’s healthcare system where a potentially life-extending drug is not readily available, forcing patients to seek treatment abroad. it also points to concerns about the decision-making process within the Cancer Control Agency regarding drug funding and prioritization.